Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent 'compound 2' at the GLP-1 receptor
Glucagon-like peptide-1 (GLP-1) mediates antidiabetogenic effects through the GLP-1 receptor (GLP-1R), which is targeted for the treatment of type 2 diabetes. Small-molecule GLP-1R agonists have been sought due to difficulties with peptide therapeutics. Recently, 6,7-dichloro-2-methylsulfonyl-3-N-te...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Default Article |
| Published: |
2010
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2134/6636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|